HCV-RNA PCR POSITIVITY IN HCV ANTIBODY NEGATIVE PATIENTS UNDERGOING HAEMODIALYSIS

Authors

  • Ismaa Ghazanfar Kiani Military hospital Rawalpinidi
  • Adil Naseer khan Ayub Medical College
  • Batool Butt Military hospital Rawalpindi
  • Sohail Sabir Military hospital Rawalpindi
  • Sundas Ejaz Military hospital Rawalpindi
  • Adeeba Perveen Military hospital Rawalpindi
  • Ejaz Ghani Military hospital Rawalpindi

Abstract

Background: It’s estimated that almost 2.2% of the world’s inhabitants suffer from hepatitis C virus (HCV). The most common cause of chronic liver disease in haemodialysis centres is due to HCV. In 1993, it was first described by Bukh and colleagues that HCV viremia can occur without any detectable antibodies to the HCV. Keeping this in mind the purpose of this cross-sectional study was to assess the frequency of HCV in haemodialysis patients by PCR who are serologically negative for HCV. Methods: This cross-sectional study was conducted from 1st June to 31st December 2016 on all haemodialysis patients at MH Rawalpindi. Epidemiological data for gender, age, duration on haemodialysis, cause of chronic renal failure and any associated risk factor for acquiring hepatitis C infection was asked. Patients undergoing haemodialysis were investigated by fourth generation ELISA for Anti HCV antibodies, HCV DNA polymerase chain reaction, HCV genotype (where required) and liver function test were also done. Results: A total of 201 patients were undergoing haemodialysis. Among these patients 73 were hepatitis “C” negative and 128 were hepatitis “C” positive. Among the 73 patients who were hepatitis C negative by ELISA method 17 (23%) were PCR positive. Of the 17 patients 13 (76.5%) were men and 4 (23.5%) were women. The mean age of the patients was 49.7±18.0 years and mean duration of haemodialysis was 4.4±4.1 months. The most common cause of CKD requiring haemodialysis was hypertension (64.7%). The most common genotype was type 1 (58.8%) followed by genotype 3 (41.2%). The mean viral load was 23583615.70 IU. Conclusion: HCV-RNA detection by PCR should be used as standard of care to detect HCV infection in patients undergoing haemodialysis.Keywords: End stage renal disease; hepatitis C virus; renal replacement therapy

Author Biography

Adil Naseer khan, Ayub Medical College

Associate Proffessor,Gatroenterology

References

Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13(17):2436–41.

Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009;13(1):9–19.

Parkash O, Hamid S. Next big threat for Pakistan Hepatocellular Carcinoma (HCC). J Pak Med Assoc 2016;66(6):735–9.

Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaaed N, Rasmussen LN, et al. Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993;43(6):1353–6.

Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002;51(3):429–33.

Bukh J, Wantzin P, Kroogsgard K, Knudsen F, Purcell TH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993;168(6):1343–8.

Seelig R, Renz M, Bottner C, Seelig HP. Hepatitis C virus infections in dialysis units: prevalence of RNA and antibodies to HCV. Ann Med 1994;26(1):45–52.

Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, et al. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation 2010;90(4):407–11.

Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol 2015;7(6):885–95.

Gómez-Gutiérrez C, Chávez-Tapia NC, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Ann Hepatol 2015;14(6):807–14.

Kuhns M, de Medina M, McNamara A, Jeffers LJ, Reddy KR, Silva M, et al. Detection of hepatitis C virus RNA in hemodialysis patients. J Am Soc Nephrol 1994;4(7):1491–7.

Seelig R, Renz M, Bottner C, Seelig HP. Hepatitis C virus infections in dialysis units: prevalence of HCV-RNA and antibodies to HCV. Ann Med 1994;26(1):45–52.

Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon 2013;13(6):e9147.

Yue YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol 2014;6(6):419–25.

Hussein MM, Mooij JM. Methods used to reduce the prevalence of hepatitis C in a dialysis unit. Saudi J Kidney Dis Transpl 2010;21(5):909–13.

Downloads

Published

2018-06-18